Economic evaluation for mass vaccination against COVID-19

Vaccine is supposed to be the most effective means to prevent COVID-19 as it may not only save lives but also reduce productivity loss due to resuming pre-pandemic activities. Providing the results of economic evaluation for mass vaccination is of paramount importance for all stakeholders worldwide....

Full description

Saved in:
Bibliographic Details
Published in:Journal of the Formosan Medical Association Vol. 120; pp. S95 - S105
Main Authors: Wang, Wei-Chun, Fann, Jean Ching-Yuan, Chang, Ray-E, Jeng, Ya-Chung, Hsu, Chen-Yang, Chen, Hsiu-Hsi, Liu, Jin-Tan, Yen, Amy Ming-Fang
Format: Journal Article
Language:English
Published: Singapore Elsevier B.V 01.06.2021
Formosan Medical Association. Published by Elsevier Taiwan LLC
Elsevier
Subjects:
BNT162 Vaccine
ChAdOx1 nCoV-19
Cost-Benefit Analysis
Cost-utility analysis
COVID-19
COVID-19 - economics
COVID-19 - prevention & control
COVID-19 Vaccines - economics
Humans
Mass Vaccination - economics
Original
Vaccine
Value of statistical life
Cost-benefit analysis
COVID-19
Value of statistical life
Vaccine
Cost-utility analysis
ISSN:0929-6646, 1876-0821, 0929-6646
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vaccine is supposed to be the most effective means to prevent COVID-19 as it may not only save lives but also reduce productivity loss due to resuming pre-pandemic activities. Providing the results of economic evaluation for mass vaccination is of paramount importance for all stakeholders worldwide. We developed a Markov decision tree for the economic evaluation of mass vaccination against COVID-19. The effectiveness of reducing outcomes after the administration of three COVID-19 vaccines (BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna), and AZD1222 (Oxford-AstraZeneca)) were modelled with empirical parameters obtained from literatures. The direct cost of vaccine and COVID-19 related medical cost, the indirect cost of productivity loss due to vaccine jabs and hospitalization, and the productivity loss were accumulated given different vaccination scenarios. We reported the incremental cost-utility ratio and benefit/cost (B/C) ratio of three vaccines compared to no vaccination with a probabilistic approach. Moderna and Pfizer vaccines won the greatest effectiveness among the three vaccines under consideration. After taking both direct and indirect costs into account, all of the three vaccines dominated no vaccination strategy. The results of B/C ratio show that one dollar invested in vaccine would have USD $13, USD $23, and USD $28 in return for Moderna, Pfizer, and AstraZeneca, respectively when health and education loss are considered. The corresponding figures taking value of the statistical life into account were USD $176, USD $300, and USD $443. Mass vaccination against COVID-19 with three current available vaccines is cost-saving for gaining more lives and less cost incurred.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0929-6646
1876-0821
0929-6646
DOI:10.1016/j.jfma.2021.05.020